{"url_path":"/sec/nrix/8-k/2026-06-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/0001549595-26-000034-index.html","accession_number":"0001549595-26-000034","cik":"0001549595","ticker":"NRIX","issuer_name":"Nurix Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1549595/0001549595-26-000034-index.html","primary_entity_key":"0001549595","primary_entity_name":"Nurix Therapeutics, Inc."},"word_count":218,"has_tables":true,"body_markdown":"Item 7.01    Regulation FD Disclosure.\n\nOn June 11, 2026, Nurix Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation at the European Hematology Association Congress (“EHA2026”) of updated clinical data from from the Phase 1a/1b study of the Company’s novel Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).\n\nA copy of the press release, which includes the data to be presented at EHA2026, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\n\nIn accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K."}